LOL laraz, thanks for illustrating the ONCX potential.
As I have stated many times, math is our friend (although maybe not for some.)
PPS is worthless by itself when calculating the value and potential value of a public company.
Even with an O/S of 200M and a PPS of .031, ONCX has a market capitalization of $6.2M.
Typically, a public company in phase 1 FDA clinical trials, support market caps of $100+M.
So using your math, a $30,000 investment in ONCX at this point could yield a 2000% gain just to get to a market cap that has been generally accepted and sustained for other biotechs in similar situations.
$30,000 times 2000% is a potential gain of over $550,000.
Even someone who had invested $160,000 and held through the slide, has the potential to realize a 300+% gain based on sustained market valuations of similar public companies.
Its just math. Just facts. Not up for debate.
Hahahaha…IMO and FWIW.
Market Data 
Markets 
AI
